Author/Authors :
Yu، نويسنده , , Sung-Liang and Chen، نويسنده , , Hsuan-Yu and Chang، نويسنده , , Gee-Chen and Chen، نويسنده , , Chih-Yi and Chen، نويسنده , , Huei-Wen and Singh، نويسنده , , Sher and Cheng، نويسنده , , Chiou-Ling and Yu، نويسنده , , Chong-Jen and Lee، نويسنده , , Yung-Chie and Chen، نويسنده , , Han-Shiang and Su، نويسنده , , Te-Jen and Chiang، نويسنده , , Ching-Cheng and Li، نويسنده , , Han-Ni and Hong، نويسنده , , Qi-Sheng and Su، نويسنده , , Hsin-Yuan and Chen، نويسنده , , Chun-Chieh and Chen، نويسنده , , Wan-Jiun and Liu، نويسنده , , Chun-Chi and Chan، نويسنده , , Wing-Kai and Chen، نويسنده , , Wei J. and Li، نويسنده , , Ker-Chau and Chen، نويسنده , , Jeremy J.W. and Yang، نويسنده , , Pan-Chyr، نويسنده ,
Abstract :
Summary
estigated whether microRNA expression profiles can predict clinical outcome of NSCLC patients. Using real-time RT-PCR, we obtained microRNA expressions in 112 NSCLC patients, which were divided into the training and testing sets. Using Cox regression and risk-score analysis, we identified a five-microRNA signature for the prediction of treatment outcome of NSCLC in the training set. This microRNA signature was validated by the testing set and an independent cohort. Patients with high-risk scores in their microRNA signatures had poor overall and disease-free survivals compared to the low-risk-score patients. This microRNA signature is an independent predictor of the cancer relapse and survival of NSCLC patients.
